All In Biotech

Free tool

FAERS Monitor: Xylocaine W/ Epinephrine

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 006488 or its brand name (Xylocaine W/ Epinephrine, Epinephrine, Lidocaine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

11,516

Serious

8,835

77% of reports

Hospitalization

4,443

Death reported

1,101

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • infusion site pain793
  • nausea741
  • drug ineffective718
  • dyspnoea650
  • off label use630
  • diarrhoea584
  • headache579
  • pain562
  • fatigue530
  • infusion site erythema494
  • dizziness474
  • vomiting454
  • hypotension422
  • pyrexia363
  • anaphylactic shock361

Reports by year received

View as table
YearReports
2004204
2005155
2006129
2007136
2008171
2009224
2010207
2011270
2012306
2013267
2014246
2015361
2016314
2017325
2018457
2019457
2020445
2021488
2022812
20231,193
20241,728
20251,615
20261,006

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,643 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infusion site painSignal793119.7111.787,535
infusion site erythemaSignal494113.6103.951,829
anaphylactic shockSignal36125.923.48,518
hypotensionSignal4223.83.5893
dyspnoeaSignal6502.11.9382
pyrexia3631.91.7161
vomiting4541.81.6153
dizziness4741.71.6151
nausea7411.71.6226
headache5791.71.6166
pain5621.71.5155
diarrhoea5841.71.5155
off label use6301.31.249
fatigue5301.21.126
drug ineffective7181.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.